NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
复制标题
DOI：
10.2337/diabetes.52.5.1210
复制
发表时间：
2003-05-01
期刊：
影响因子：
7.7
通讯作者：
Haffner, SM
中科院分区：
文献类型：
--
作者：
Alexander, CM;Landsman, PB;Haffner, SM
尽管代谢综合征的各个组成部分与冠心病（CHD）风险增加明显相关，但我们希望量化代谢综合征患者CHD患病率的增加。第三次全国健康和营养检查调查（NHANES III）用于根据代谢综合征（国家胆固醇教育计划[NCEP]定义）伴或不伴糖尿病对50岁以上的成年人进行分类。确定每组的人口统计学和危险因素信息，以及每组符合代谢综合征特定标准的比例。然后确定各组的CHD患病率。代谢综合征是非常常见的，在50岁以上的美国人口中，有44%的人符合NCEP标准。相比之下，无代谢综合征的糖尿病并不常见（占糖尿病患者的113%）。50岁以上无代谢综合征的美国老年人（无论是否患有糖尿病）的CHD患病率最低（8.7%无糖尿病，7.5%有糖尿病）。与代谢综合征患者相比，无代谢综合征的糖尿病患者CHD患病率没有增加。有代谢综合征而无糖尿病者CHD患病率较高（13.9%），同时有代谢综合征和糖尿病者CHD患病率最高（19.2%）。代谢综合征是冠心病的单因素预测因子（OR 2.07，95% CI 1.66-2.59）。然而，血压，高密度脂蛋白胆固醇，糖尿病，而不是代谢综合征的存在，是显着的多变量预测冠心病流行。冠心病的患病率随着代谢综合征的出现而明显增加。在糖尿病人群中，代谢综合征的患病率很高，合并代谢综合征的糖尿病人群中冠心病的患病率最高。在所有糖尿病患者中，CHD的患病率比无糖尿病的代谢综合征患者高。然而，没有代谢综合征的糖尿病患者与没有代谢综合征的人相比，冠心病的患病率并没有增加。
Although the individual components of the metabolic syndrome are clearly associated with increased risk for coronary heart disease (CHD), we wanted to quantify the increased prevalence of CHD among people with metabolic syndrome. The Third National Health and Nutrition Examination Survey (NHANES III) was used to categorize adults over 50 years of age by presence of metabolic syndrome (National Cholesterol Education Program [NCEP] definition) with or without diabetes. Demographic and risk factor information was determined for each group, as well as the proportion of each group meeting specific criteria for metabolic syndrome. The prevalence of CHD for each group was then determined. Metabolic syndrome is very common, with similar to44% of the U.S. population over 50 years of age meeting the NCEP criteria. In contrast, diabetes without metabolic syndrome is uncommon (113% of those with diabetes). Older Americans over 50 years of age without metabolic syndrome regardless of diabetes status had the lowest CHD prevalence (8.7% without diabetes, 7.5% with diabetes). Compared with those with metabolic syndrome, people with diabetes without metabolic syndrome did not have an increase in CHD prevalence. Those with metabolic syndrome without diabetes had higher CHD prevalence (13.9%), and those with both metabolic syndrome and diabetes had the highest prevalence of CHD (19.2%) compared with those with neither. Metabolic syndrome was a significant univariate predictor of prevalent CHD (OR 2.07, 95% CI 1.66-2.59). However, blood pressure, HDL cholesterol, and diabetes, but not presence of metabolic syndrome, were significant multivariate predictors of prevalent CHD. The prevalence of CHD markedly increased with the presence of metabolic syndrome. Among people with diabetes, the prevalence of metabolic syndrome was very high, and those with diabetes and metabolic syndrome had the highest prevalence of CHD. Among all individuals with diabetes, prevalence of CHD was increased compared with those with metabolic syndrome without diabetes. However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither.